# US 2013/0253046 A1 · Methods of treating cancer comprising targeting nqo1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253046 A1
- Document ID: US20130253046A1
- Status: Published application
- Kind: A1
- Application number: 13/820,127
- Filed: 2011-09-22
- Published: 2013-09-26
- Earliest claimed: 2010-09-22
- Assignees: Board of Regents, The University of Texas System
- Inventors: David BOOTHMAN
- Web page: https://patentgrep.com/patent/US20130253046A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- C12Q 1/26: involving oxidoreductase
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition.

## Claims

### Claim at position 1

1: A method of determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, comprising measuring the protein level of the NQO1 expression and the catalase expression in the cancer cells in the individual, wherein a ratio of the NQO1 level over the catalase level in the cancer cells from the individual being at least about 50-fold of the ratio of a normal tissue indicates that the individual is suitable for the treatment.

### Claim 2

A method of predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, comprising measuring the protein level of the NQO1 expression and the catalase expression in the cancer cells in the individual, wherein a ratio of the NQO1 level over the catalase level in the cancer cells from the individual being at least about 50-fold of the ratio of a normal tissue indicates that the individual is more likely to be responsive to the treatment.

### Claim 3

A method of treating an individual with cancer, comprising administering an effective amount of an NQO1 bioactivatable drug to the individual, wherein the individual is selected for the treatment if the ratio of the NQO1 level over the catalase level in the cancer cells from the individual is at least about 50-fold of the ratio in a normal tissue.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ratio of the NQO1 level over the catalase level in the cancer cells from the individual is at least about 60-fold or at least about 70-fold of the ratio in a normal tissue.

### Claim 5 (depends on 4)

The method of claim 4, wherein the normal tissue is from the individual.

### Claim 6

A method of determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, comprising measuring the protein level of NQO1 expression in the cancer cells from the individual, wherein the NQO1 enzymatic activity being at least about 50 units in the cancer cells indicates that the individual is suitable for the treatment.

### Claim 7

A method of predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, comprising measuring the protein level of NQO1 expression in the cancer cells from the individual, wherein the NQO1 enzymatic activity being at least about 50 units in the cancer cells indicates that the individual is more likely to be responsive to the treatment.

### Claim 8

A method of treating an individual with cancer, comprising administering an effective amount of an NQO1 bioactivatable drug to the individual, wherein the individual is selected for the treatment if the NQO1 enzymatic activity in the cancer cells of the individual is at least about 50 units.

### Claim 9 (depends on 6)

The method of claim 6, wherein NQO1 enzymatic activity in the cancer cells of the individual is at least about 60 units, at least about 70 units, at least about 80 units, or at least about 90 units.

### Claim 10

A method of determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, comprising detecting an NQO1 gene polymorphism C465T mutation in a sample from the individual, wherein the presence of C465T/C465T polymorphism indicates that the individual is suitable for the treatment.

### Claim 11

A method of predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, comprising detecting an NQO1 gene polymorphism C465T mutation in a sample from the individual, wherein the presence of C465T/C465T polymorphism indicates that the individual is likely to be responsive to the treatment.

### Claim 12

A method of treating an individual with cancer, comprising administering an effective amount of an NQO1 bioactivatable drug to the individual, wherein the individual is selected for the treatment based on the presence of C465T/C465T polymorphism in a sample from the individual.

### Claim 13 (depends on 10)

The method of claim 10, wherein the sample is a cancer tissue sample or a PBMC sample.

### Claim 14 (depends on 1)

The method of claim 1, further comprising monitoring treatment of an NQO1 bioactivatable drug in an individual by measuring one or more protein levels in cancer cells from the individual before and after the treatment, wherein the protein measured is selected from the group consisting of NQO1, catalase, small μ-calpain subunit, large μ-calpain subunit, apoptosis inducing factor (AIF), and PARP-1.

### Claim 15 (depends on 1)

The method of claim 1, wherein the NQO1 bioactivatable drug is a β-lapachone compound, streptonigrin, or deoxynyboquinone (DNQ).

### Claim 16 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer, prostate cancer, breast cancer, pancreatic cancer, colon cancer or melanoma.

### Claim 17 (depends on 1)

The method of claim 1, wherein the protein level of the NQO1 expression and/or the catalase expression is measured by the enzymatic activity or the amount of the protein in the cancer cells and in the normal tissue from the individual.

### Claim 18 (depends on 1)

The method of claim 1, wherein the individual is a human.

### Claim 19 (depends on 1)

The method of claim 1, wherein the normal tissue is an associated normal tissue.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer cells are from a cancer biopsy from the individual or circulating cancer cells from the individual.

### Claim 21

A method for treating cancer in an individual in need thereof, comprising administering a DNA damaging therapy to an individual in need thereof and an NQO1 bioactivatable drug.

### Claim 22 (depends on 21)

The method of claim 21, further comprising determining the NQO1 status of the individual, wherein the NQO1 bioactivatable drug is administered to the individual if the cancer is NQO1 positive and not administered to the individual if the cancer is NQO1 negative.

### Claim 23 (depends on 21)

The method of claim 21, wherein the tumor is exposed to the NQO1 bioactivatable drug for at least 2 hours.

### Claim 24 (depends on 21)

The method of claim 21, wherein the doses of DNA damaging therapies are sub-threshold or standard.

### Claim 25 (depends on 21)

The method of claim 21, wherein the DNA damaging therapy is ionizing radiation, chemotherapeutics or photodynamic (PDT) therapeutics.

### Claim 26 (depends on 21)

The method of claim 21, wherein the DNA damaging therapy and the NQO1 bioactivatable drug are administered simultaneously.

### Claim 27 (depends on 21)

The method of claim 21, wherein the NQO1 bioactivatable drug is administered immediately after the administration of the DNA damaging therapy.

### Claim 28 (depends on 21)

The method of claim 21, wherein the NQO1 bioactivatable drug is administered within about 1 to about 24 hours after the administration of the DNA damaging therapy.

### Claim 29 (depends on 21)

The method of claim 21, wherein the NQO1 bioactivatable drug is β-lap, streptonigrin, or DNQ.

### Claim 30 (depends on 21)

The method of claim 21, wherein the NQO1 bioactivatable drug is a prodrug.

### Claim 31 (depends on 21)

The method of claim 21, wherein the NQO1 bioactivatable drug is formulated with cyclodextrins or with micelles.

### Claim 32 (depends on 21)

The method of claim 21, wherein the NQO1 bioactivatable drug is formulated with SPIO-micelles; ligand-encoded (e.g., αvβ3) micelles.
